Academic Journal
Q1Brain Pathology
About Brain Pathology
Brain Pathology is a scholarly journal published by Wiley-Blackwell. SCImago 2025 lists it in Q1, with an SJR of 1.955 and H-index of 159.
Coverage: 1990-2026. Research categories: Neurology (clinical) (Q1); Neuroscience (miscellaneous) (Q1); Pathology and Forensic Medicine (Q1).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-03-17. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Glioma Diagnosis and Treatment; Alzheimer's disease research and treatments; Neuroinflammation and Neurodegeneration Mechanisms; Neurological diseases and metabolism; Parkinson's Disease Mechanisms and Treatments; Meningioma and schwannoma management.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Society News
Audrey Rousseau
2026-11 · DOI: 10.1111/bpa.70149Issue Information
2026-11 · DOI: 10.1111/bpa.70146Gliomas with pleomorphic and pseudopapillary features ( GPAP ) are circumscribed tumors with targetable mutations, prolonged survival, and frequent tumor predisposition
Alberto Picca, Valeria Barresi, Aude Trinquet, Luca Bertero et al.
2026-09-29 · DOI: 10.1111/bpa.70153Spatial transcriptomic analysis of neurons at the glioma infiltration front: A case study
Kaishi Satomi, Hirokazu Takami, Hiromi Onizuka, Kuniaki Saito et al.
2026-09-29 · DOI: 10.1111/bpa.70154Correction to “Molecular and clinical features of a Japanese medulloblastoma cohort: Subgroup‐specific prognostic stratification using economical/accessible diagnostic methods”
2026-09-21 · DOI: 10.1111/bpa.70148A 38‐year‐old female with seizures and a cortico–subcortical mass
Marjolein Billen, Annemerel Van Wylick, Anne‐Marie Vanbinst, Hendrik Everaert et al.
2026-09-20 · DOI: 10.1111/bpa.70150Neuropathology of a patient with Parkinson's disease and biallelic expansion in RFC1
Jussi Sipilä, Tuomas Rauramaa, Laura Kytövuori, Kari Majamaa et al.
2026-09-18 · DOI: 10.1111/bpa.70152Enhancement of the leptomeninges in a young man
Jayden Ray, Mohammad Alberawi, Andrew Bauer, Kar‐Ming Fung et al.
2026-09-16 · DOI: 10.1111/bpa.70145Circumscribed Meningeal Melanocytic Neoplasms: CNS WHO Grade, Molecular Profile, and Clinical Outcomes
Yi Zhu, Nishika Karbhari, Timothy J. Kaufmann, Aditya Raghunathan et al.
2026-09-15 · DOI: 10.1111/bpa.70147Dysregulated TIE ‐2 expression in Alzheimer's disease: Further considerations on regional specificity and shedding evidence
Shi‐qi Zhang, Meichen Liu
2026-09-13 · DOI: 10.1111/bpa.70151PTEN homozygous deletion is a negative prognostic factor in tumor treating fields‐treated glioblastoma, IDH wildtype patients
Jakob Nückles, Claudius Jelgersma, Christin Siewert, Brendan Osberg et al.
2026-09-10 · DOI: 10.1111/bpa.70143Molecular profiling of pediatric medulloblastoma in Kazakhstan: Genomic alterations, subgroup distribution, and survival
Aidos Bolatov, Askhat Zhakupov, Aizhan Abdikadirova, Malika Sapargaliyeva et al.
2026-09-08 · DOI: 10.1111/bpa.70144Clinical evaluation of the CrossNN DNA methylation classifier for central nervous system tumors
Jonas Dahnoun, Léon C. van Kempen, Senada Koljenović, Ken Op de Beeck et al.
2026-09-02 · DOI: 10.1111/bpa.70137Immunohistochemistry as a tool for identifying PDGFRA amplification in central nervous system tumors
Arnault Tauziède‐Espariat, Guilhem Amargos, Farah Sassi, Lauren Hasty et al.
2026-09-02 · DOI: 10.1111/bpa.70142Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α‐synuclein preformed fibrils‐induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines
Paz Cartas‐Cejudo, Marina De Miguel, Leire Extramiana, Mercedes Lachén‐Montes et al.
2026-08-30 · DOI: 10.1111/bpa.70140Complement receptor C3aR marks heterogeneous tumor‐associated macrophage states associated with improved survival in IDH ‐wildtype glioblastoma
Marion Imara, Yosra Bedoui, Théotime Pignolet, Sebastien Freppel et al.
2026-08-30 · DOI: 10.1111/bpa.70141AOSNP‐ADAPTR resource level‐based recommendations on practical diagnostic strategies for medulloblastomas and other embryonal tumors
Chitra Sarkar, Maysa Al‐Hussaini, Vani Santosh, Vaishali Suri et al.
2026-08-29 · DOI: 10.1111/bpa.70136Brain calcification‐associated JAM2 pathogenic mutations impair JAM2 – JAM3 tight junction structure and the blood–brain barrier integrity
Dehao Yang, Lebo Wang, Chenxin Ying, Yihua Shi et al.
2026-08-27 · DOI: 10.1111/bpa.70139Reviews
Community Reviews
Version History
October 4, 2026 at 8:47 pm
September 25, 2026